secwatch.observer — SEC 8-K summary
======================================

Issuer:     Relay Therapeutics, Inc. (RLAY)
CIK:        0001812364
Form:       8-K
Filed at:   2022-09-08T23:59:59+00:00
Accession:  0000950170-22-018205
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relay Therapeutics reports 88% ORR at RP2D for RLY-4008 in FGFR2 fusion CCA
---------------------------------------------------------------------------

- At RP2D (70 mg QD), ORR 88% (15/17), confirmed ORR 82.4% (14/17), disease control rate 100%.
- All-dose ORR 63.2% (24/38), confirmed ORR 57.9% (22/38), DCR 94.7%.
- 68% of patients remain on treatment; median follow-up 6 months (range <0.1-18.5).
- No grade 4/5 treatment-related AEs; most common low-grade stomatitis (48%) and PPE (46%).
- Abstract selected for oral presentation at ESMO Congress 2022 on Sept 11.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1812364/000095017022018205/0000950170-22-018205-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1812364/000095017022018205/rlay-20220907.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-018205

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer